1 of 1
Story summary
- Danaher Corporation generated $24.6 billion in revenue in 2025 and net income of $3.6 billion, signaling profitability in biotech and diagnostics.
- Danaher expects revenue growth of 3–6% in 2026 and earnings per share of $8.35–$8.55.
- Its diversified portfolio includes tools for drug development and diagnostics, aligning with aging populations and precision medicine.
- Analysts maintain a positive outlook, noting Danaher's resilience and strategic initiatives, including Masimo Corp. acquisition for $9.9 billion.
